Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.11.4207 on August 20 2007

Journal of Clinical Oncology, Vol 25, No 27 (September 20), 2007: pp. 4293-4297
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zinzani, P. L.
Right arrow Articles by Baccarani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zinzani, P. L.
Right arrow Articles by Baccarani, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Pier Luigi Zinzani, Gerardo Musuraca, Monica Tani, Vittorio Stefoni, Enrica Marchi, Mariapaola Fina, Cinzia Pellegrini, Lapo Alinari, Enrico Derenzini, Antonio de Vivo, Elena Sabattini, Stefano Pileri, Michele Baccarani

From the Institute of Hematology and Medical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy

Address reprint requests to Pier Luigi Zinzani, MD, Institute of Hematology and Oncology "L. & A. Seràgnoli", Via Massarenti 9, 40138 Bologna, Italy; e-mail: plzinzo{at}med.unibo.it

Purpose To determine the antitumor activity of the proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma unspecified (PTCLU) with isolated skin involvement.

Patients and Methods From May 2005 to June 2006 at our institute, we treated patients with previously pretreated CTCL or PTCLU using bortezomib as a single agent, at a dose of 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, every 21 days for a total of six cycles.

Results Fifteen patients were registered, of whom 12 (10 CTCL, all mycosis fungoides, and two PTCLU with isolated skin involvement) were assessable. The overall response rate was 67%, with two (17%) complete remissions and six (50%) partial remissions. The remaining four patients had disease progression. Histologically, the responder patients were seven with CTCL and one with PTCLU with isolated skin involvement. All responses were durable, lasting from 7 to 14 or more months. Overall, the drug was well tolerated, with no grade 4 toxicity. The most common grade 3 toxicities were neutropenia (n = 2), thrombocytopenia (n = 2), and sensory neuropathy (n = 2).

Conclusion This study suggests that bortezomib was well tolerated and has significant single-agent activity in patients with cutaneous T-cell lymphoma.

published online ahead of print at www.jco.org on August 20, 2007.

Supported in part by Sezione di Bologna dell’Associazione Italiana contro le leucemie, linformi e mieloma (BolognAIL).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BloodHome page
H. M. Prince, S. Whittaker, and R. T. Hoppe
How I treat mycosis fungoides and Sezary syndrome
Blood, November 12, 2009; 114(20): 4337 - 4353.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
P. L. Zinzani, F. Venturini, V. Stefoni, M. Fina, C. Pellegrini, E. Derenzini, L. Gandolfi, A. Broccoli, L. Argnani, F. Quirini, et al.
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
Ann. Onc., November 3, 2009; (2009) mdp508v1.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Delmonte, M. Ghielmini, and C. Sessa
Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas
Oncologist, May 1, 2009; 14(5): 511 - 525.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
B. Pro
Novel Agents in Peripheral T-cell Lymphomas
ASCO Educational Book, January 1, 2009; 2009(1): 486 - 489.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. Lee, C. Suh, H. J. Kang, B.-Y. Ryoo, J. Huh, Y. H. Ko, H.-S. Eom, K. Kim, K. Park, and W. S. Kim
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma
Ann. Onc., December 1, 2008; 19(12): 2079 - 2083.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W.-L. Zhao, Y.-Y. Liu, Q.-L. Zhang, L. Wang, C. Leboeuf, Y.-W. Zhang, J. Ma, J.-F. Garcia, Y.-P. Song, J.-M. Li, et al.
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor
Blood, April 1, 2008; 111(7): 3867 - 3871.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
S. M. Horwitz
Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas
Hematology, January 1, 2008; 2008(1): 289 - 296.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online